CATALYST PHARMACEUTICAL Aktie

>CATALYST PHARMA Aktienkurs

21.49 EUR +0.3% (TradegateBSX)

Ask: 21.44 EUR / 900 Stück

Bid: 21.37 EUR / 1200 Stück

Tagesumsatz: 20 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>CATALYST PHARMA Performance

1 Woche: +4,7%

1 Monat: +4,6%

3 Monate: +9,2%

6 Monate: +20,5%

1 Jahr: -0,7%

laufendes Jahr: +4,3%

>CATALYST PHARMACEUTICAL Aktie

Name:

CATALYST PHARMACEUTICAL

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US14888U1016 / A0LCUL

Symbol/ Ticker:

CN2 (Frankfurt) / CPRX (NASDAQ)

Kürzel:

FRA:CN2, ETR:CN2, CN2:GR, NASDAQ:CPRX

Index:

Webseite:

https://catalystpharma.co..

Profil:

Catalyst Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, particularly in neuromuscular, neuro..
>Volltext..

Marktkapitalisierung:

2625.9 Mio. EUR

Unternehmenswert:

2024.74 Mio. EUR

Umsatz:

510.25 Mio. EUR

EBITDA:

256.38 Mio. EUR

Nettogewinn:

185.67 Mio. EUR

Gewinn je Aktie:

1.52 EUR

Schulden:

2.41 Mio. EUR

Liquide Mittel:

614.37 Mio. EUR

Operativer Cashflow:

180.77 Mio. EUR

Bargeldquote:

4.82

Umsatzwachstum:

5.57%

Gewinnwachstum:

15.27%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CATALYST PHARMACEUTICAL, CATALYST PHARMACEUTICALS, CATALYST PHARMA

Letzte Datenerhebung:

05.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 122.12 Mio. St.

Frei handelbar: 89.84%

Leerverk. Aktien: 7.95%

Rückkaufquote: 0.35%

Mitarbeiter: 182

Umsatz/Mitarb.: 2.8 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 35.69%

Bewertung:

KGV: 14.95

KGV lG: 13.39

KUV: 5.27

KBV: 3.23

PEG-Ratio: 0.5

EV/EBITDA: 7.9

Rentabilität:

Bruttomarge: 78.82%

Gewinnmarge: 36.39%

Operative Marge: 43.77%

Managementeffizenz:

Gesamtkaprendite: 21.86%

Eigenkaprendite: 25.49%

>Peer Group

Gesundheit, Neurologische- & psychische Behandlung/ Medizin

>CATALYST PHARMA Chart & Kurs - NASDAQ

>CATALYST PHARMA News

11.03.26 - 03:12	Catalyst Pharmaceuticals auf Barclays-Konferenz: Zwischen strategischem Wachstum und Herausforderungen (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.03.26 - 14:06

Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference (GlobeNewswire EN)

CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real‑world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Catalyst will also sponsor a vamorolone-focused MDA Industry Forum with Santhera Pharmaceuticals....

26.02.26 - 17:30	Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
	CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance....

26.02.26 - 16:12	Catalyst Pharmaceuticals übertrifft Erwartungen im 4. Quartal, Aktie gibt dennoch nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

25.02.26 - 22:33	Catalyst Pharmaceuticals, Inc. Non-GAAP EPS of $0.68 beats by $0.18, revenue of $152.6M beats by $9.85M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.02.26 - 22:15	Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance (GlobeNewswire EN)
	Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues...

24.02.26 - 17:30	Here′s Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock (Zacks)
	The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

24.02.26 - 14:06

Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference (GlobeNewswire EN)

CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, being held in Miami, Florida....

18.02.26 - 17:30	Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
	Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

11.02.26 - 14:06	Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 (GlobeNewswire EN)
	The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET...

08.01.26 - 14:06

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America′s Most Successful Small-Cap Companies (GlobeNewswire EN)

CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list....

05.01.26 - 14:06	The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) (GlobeNewswire EN)
	Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive...

31.12.25 - 17:36	Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What′s Behind the Move? (Fool)
	The exercise-and-sell transaction came as the rare disease drugmaker reported strong quarterly results....

23.12.25 - 17:30	Here′s Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

17.12.25 - 17:30	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks)
	Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year....

17.12.25 - 05:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Catalyst Pharmaceuticals im Wert von 621920 USD (Insiderkauf)
	Harper, Molly - Aufsichtsrat - Tag der Transaktion: 2025-12-12...

16.12.25 - 16:00	If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It′d Be Worth Now (Zacks)
	Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards....

15.12.25 - 14:06

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026....

02.12.25 - 17:30	Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term (Zacks)
	The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

29.11.25 - 05:01	Insiderhandel: Chief Commercial Officer verkauft Aktien von Catalyst Pharmaceuticals im Wert von 256244 USD (Insiderkauf)
	Del, Carmen Jeffrey - Vorstand - Tag der Transaktion: 2025-11-26...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram